Aclarion Elects Board, Approves Equity Plan as Nociscan Volumes Surge 196%
ACON•At its June 4 meeting, Aclarion stockholders elected seven directors, ratified Haynie & Company as auditor and approved an amendment to its 2022 equity incentive plan. The company reported 196% year-over-year growth in Nociscan scan volumes in Q1, expanded UK insurance coverage and advanced its U.S. reimbursement strategy.
1. Annual Meeting Approvals
Aclarion stockholders approved all proposals at the June 4, 2026 annual meeting, including election of seven board members, ratification of Haynie & Company as independent auditor and an amendment to the 2022 equity incentive plan.
2. Board of Directors Election
The newly elected directors—Jeffrey Thramann, Brent Ness, Stephen Deitsch, Scott Breidbart, David Neal, William Wesemann and Amanda Williams—will serve until the 2027 annual meeting, reinforcing governance oversight for Aclarion's commercial and clinical objectives.
3. Nociscan Scan Volume Growth and Insurance Expansion
In Q1 2026, the company achieved 196% year-over-year growth in Nociscan scan volumes, secured broader insurance coverage in the United Kingdom and progressed its reimbursement strategy in the United States.
4. Strategic Focus and Outlook
Management emphasized disciplined execution across clinical and reimbursement initiatives with planned catalysts for the remainder of 2026 aimed at driving patient insights and shareholder value.
